HOME >> BIOLOGY >> NEWS
Researchers developing technology to outsmart metastasized cancers

WEST LAFAYETTE, Ind. News that a malignant tumor has spread to other parts of the body seems like a death knell to the ears of many cancer patients. But Endocyte Inc. and Purdue University researchers are developing treatment methods that ultimately may cure some cancers, even those that have reached an advanced stage.

Many types of cancer cells have a great affinity for folate a form of water-soluble B vitamin because they need the nutrient in order to grow and divide. In fact, cancer cells have evolved a mechanism to capture folate more effectively than normal cells. Making use of this selectivity, researchers have developed a way to trick cancer cells into attracting and even ingesting anticancer agents that are attached to folate molecules. As a result, these chemotherapeutic agents can be delivered more specifically to cancer cells while leaving the surrounding normal tissue unharmed.

One form of this "Trojan Horse" therapeutic approach (folate-targeted immunotherapy) was used by a joint Purdue-Endocyte research team to successfully treat more than 200 mice with late-stage metastatic disease. The results of these studies were published in the May Journal of Cancer Immunology and Immunotherapy.

"It's using cancer's nutritional needs against itself," said Philip Low, Purdue's Joseph F. Foster Distinguished Professor of Chemistry who led the research team that discovered this diagnostic and treatment method. "We are essentially slipping medicine in with cancer's favorite food."

The discovery has thus far yielded two different but complementary treatment methods that involve attaching various markers (folate-targeted immunotherapy) or anticancer agents (folate-targeted chemotherapy) to the vitamin.

The treatment method that "marks" cancer will be tested in Phase I Food and Drug Administration-regulated human clinical trials beginning in November. The objective of this method is to force the body's immune syste
'"/>

Contact: Jeanine Phipps
jeanine@purdue.edu
765-496-3133
Purdue University
20-Jun-2002


Page: 1 2 3 4

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/23/2015)... July 23, 2015 Aware, Inc. (NASDAQ: AWRE ... reported financial results for its second quarter ended June 30, ... 2015 was $4.5 million, a decrease of 33% compared to ... in the second quarter of 2015 was $0.3 million, or ... $0.04 per diluted share, in the same period a year ...
(Date:7/21/2015)... 21, 2015 Passwords have proven futile ... the recent U.S. Office of Personnel Management breach. ... infosec conundrum, but developers and end-users are concerned ... this dilemma, Biometrics-as-a-Service provider HYPR Corp. announced today ... for third party integration. A ...
Breaking Biology News(10 mins):The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6HYPR Corp. Launches Industry First Biometric Tokenization Platform 2HYPR Corp. Launches Industry First Biometric Tokenization Platform 3HYPR Corp. Launches Industry First Biometric Tokenization Platform 4
(Date:7/29/2015)... /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ) today announced ... Officer has resigned.  The Company has hired Andrew ... in December 2014, as full time interim CFO and ... Andy Ashworth began his employment today, ... transition.  Andy was the Company,s CFO from September 2011 ...
(Date:7/29/2015)... ... July 29, 2015 , ... G-CON Manufacturing, Inc., the leading ... 2nd generation cell therapy POD® design. The 2nd generation portfolio not only delivers ... new POD® design. , “G-CON first offered our miniPOD CT product line ...
(Date:7/29/2015)...  AmnioChor Inc., an early stage biotech startup based ... announce that the Musculoskeletal Transplant Foundation of ... their seed round of development of the proprietary AmnioCept™ ... AmnioChor,s technology allows cryopreservation of the amniotic ... living within those tissues. Amnion is a well-established source ...
(Date:7/29/2015)... July 29, 2015  Indivior PLC (LON: INDV) today ... nasal spray was accepted and received Priority Review by ... treatment of opioid overdose. This naloxone nasal spray comes ... for optimal absorption into the nasal mucosa. 1 ... so individuals may be better equipped to help an ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 2G-CON Manufacturing Launches Their 2nd Generation Cell Therapy Cleanroom POD® 3The Musculoskeletal Transplant Foundation Agrees to Invest in AmnioChor 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 2Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 3Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 4Indivior PLC Announces FDA Acceptance of Naloxone Nasal Spray New Drug Application With Priority Review 5
Cached News: